Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Signaling Pathways Involved in the Regulation of mRNA Translation.

Roux PP, Topisirovic I.

Mol Cell Biol. 2018 May 29;38(12). pii: e00070-18. doi: 10.1128/MCB.00070-18. Print 2018 Jun 15. Review.

2.

Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway.

Liu Z, Liu H, Yuan X, Wang Y, Li L, Wang G, Song J, Shao Z, Fu R.

Oncol Lett. 2018 Apr;15(4):4079-4086. doi: 10.3892/ol.2018.7865. Epub 2018 Jan 26.

3.

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.

Rebello RJ, Pearson RB, Hannan RD, Furic L.

Genes (Basel). 2017 Feb 16;8(2). pii: E71. doi: 10.3390/genes8020071. Review.

4.

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.

van Attekum MHA, Terpstra S, Slinger E, von Lindern M, Moerland PD, Jongejan A, Kater AP, Eldering E.

Oncogene. 2017 Jun 29;36(26):3651-3660. doi: 10.1038/onc.2016.515. Epub 2017 Feb 13.

6.

Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.

Nair JR, Caserta J, Belko K, Howell T, Fetterly G, Baldino C, Lee KP.

Leukemia. 2017 Aug;31(8):1715-1726. doi: 10.1038/leu.2016.379. Epub 2016 Dec 23.

7.

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A.

Nat Med. 2016 Nov;22(11):1321-1329. doi: 10.1038/nm.4213. Epub 2016 Oct 24.

8.

Pim2 is important for regulating DNA damage response in multiple myeloma cells.

Ramachandran J, Santo L, Siu KT, Panaroni C, Raje N.

Blood Cancer J. 2016 Aug 26;6(8):e462. doi: 10.1038/bcj.2016.73.

9.

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.

Peters TL, Li L, Tula-Sanchez AA, Pongtornpipat P, Schatz JH.

Oncotarget. 2016 Sep 27;7(39):63362-63373. doi: 10.18632/oncotarget.11457.

10.

Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation.

Velásquez C, Cheng E, Shuda M, Lee-Oesterreich PJ, Pogge von Strandmann L, Gritsenko MA, Jacobs JM, Moore PS, Chang Y.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8466-71. doi: 10.1073/pnas.1607768113. Epub 2016 Jul 11.

11.

Coordinated Regulation of Cap-Dependent Translation and MicroRNA Function by Convergent Signaling Pathways.

Olejniczak SH, La Rocca G, Radler MR, Egan SM, Xiang Q, Garippa R, Thompson CB.

Mol Cell Biol. 2016 Aug 26;36(18):2360-73. doi: 10.1128/MCB.01011-15. Print 2016 Sep 15.

12.

Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.

Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V.

Leuk Lymphoma. 2016 Dec;57(12):2863-2873. Epub 2016 Apr 7.

13.

Insulin receptor substrate 1 is a substrate of the Pim protein kinases.

Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, Ball LE, Warfel NA, Kraft AS.

Oncotarget. 2016 Apr 12;7(15):20152-65. doi: 10.18632/oncotarget.7918.

14.

4E-BP1, a multifactor regulated multifunctional protein.

Qin X, Jiang B, Zhang Y.

Cell Cycle. 2016;15(6):781-6. doi: 10.1080/15384101.2016.1151581. Review.

15.

mTOR-Dependent and Independent Survival Signaling by PI3K in B Lymphocytes.

Kaileh M, Vazquez E, MacFarlane AW 4th, Campbell K, Kurosaki T, Siebenlist U, Sen R.

PLoS One. 2016 Jan 19;11(1):e0146955. doi: 10.1371/journal.pone.0146955. eCollection 2016.

16.

Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.

An N, Xiong Y, LaRue AC, Kraft AS, Cen B.

Cancer Res. 2015 Dec 15;75(24):5318-28. doi: 10.1158/0008-5472.CAN-15-0544.

17.

Cell Death Signaling.

Green DR, Llambi F.

Cold Spring Harb Perspect Biol. 2015 Dec 1;7(12). pii: a006080. doi: 10.1101/cshperspect.a006080. Review.

18.

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.

Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.

Oncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.

19.

MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.

Cai Q, Medeiros LJ, Xu X, Young KH.

Oncotarget. 2015 Nov 17;6(36):38591-616. doi: 10.18632/oncotarget.5774. Review.

20.

Targeting the Pim kinases in multiple myeloma.

Keane NA, Reidy M, Natoni A, Raab MS, O'Dwyer M.

Blood Cancer J. 2015 Jul 17;5:e325. doi: 10.1038/bcj.2015.46. Review.

Supplemental Content

Support Center